Novo Nordisk A/S

Eli Lilly and Company

The Danish company's shares have halved in price in 2025 amid doubts about its ability to conquer the market

First obesity pill: US approves Novo drug, how will the market react?

ABIVAX Societe Anonyme

The YTD gain for the French biotech is still almost 1,300% 

STOXX 600 YTD leader Abivax tumbles 10% in a day on 9m25 earnings

Pfizer Inc.

Pfizer expects revenue and profit to decline in 2026 due to weaker demand for vaccines and other products related to Covid-19. Analysts note that the company is trying to offset the pressure on its performance by cutting costs and increasing investments in research and development, but do not see any significant drivers for the stock's revaluation in the coming year.

Pfizer expects performance to fall due to lower sales of Covid vaccines. Shares fall

ServiceNow, Inc.

China's retail sales growth posted its worst gain on record, barring the Covid-19 pandemic period. HBM Healthcare InvestmentsBank of Japan is preparing to start selling off JPY83 trillion worth of ETFs. AI solutions developer ServiceNow is in talks to buy cybersecurity startup Armis for $7 billion. These and other topics are covered in our review of key events for the morning of December 15.

Highlights for the morning: copper outlook, Japan's central bank prepares ETF sell-off and $7 bln deal

Moderna, Inc.

Novavax, Inc.

The U.S. Food and Drug Administration has threatened to tighten its vaccine approval process

Moderna and Novavax shares fall amid reports of 10 likely deaths after vaccination

Merck & Co., Inc.

Regeneron Pharmaceuticals, Inc.

Increased volatility and doubts about AI's prospects have pushed the market toward defensive stocks

Healthcare has become a safe haven for investors: the sector grew by 10% in November


The White House also secured reductions in the cost of Wegovy and Pfizer's cancer drug

Novo will cut the price of Ozempic by 71% for older Americans. This will hinder revenue growth

Olema Pharmaceuticals, Inc.

Roche Holding AG

Shares of Olema Pharmaceuticals, a small-cap maker of cancer drugs, <a href="https://finance.yahoo.com/quote/OLMA/">soared</a>&nbsp;almost 200% last week, November 18-24. Investors were <a href="https://www.roche.com/media/releases/med-cor-2025-11-18">reacting</a>&nbsp;to positive news on clinical trials from Swiss pharma giant Roche. Olema is advancing a therapy with a similar mechanism of action, meaning Roche’s success has reduced the perceived risks of investing in Olema, Freedom Broker explains. Against this backdrop, at least two Wall Street analysts have <a href="https://finance.yahoo.com/quote/OLMA/">raised</a>&nbsp;their target price on Olema shares.

Oncology drugmaker Olema triples in a week after latest Roche data eases sector risks

The failure of a trial of a tablet version of Ozempic against Alzheimer's disease has come as a blow to Danish pharmaceutical manufacturer Novo Nordisk. The results showed no slowing of symptoms, and the company refused to extend the trial. Analysts note: it was one of the few opportunities for Novo to quickly strengthen its position amid increasing competition. The company's shares collapsed in Copenhagen by 12.4%, falling to their lowest level since July 2021.

Ozempic's failed Alzheimer's trial collapses Novo shares to lowest since 2021

The company is starting to resemble the tech giants from "The Magnificent Seven" again, analysts said

Eli Lilly became the first pharma giant to be capitalized at $1 trillion. What's next?

LifeMD, Inc.

Shares of telemedicine platform LifeMD <a href="https://finance.yahoo.com/quote/LFMD/">plunged</a>&nbsp;25% in early trading this morning, November 18. The company’s quarterly results came in weaker than Wall Street expected, and the management also lowered its revenue outlook for the year. The stock was not supported even by an agreement with Novo Nordisk that LifeMD <a href="https://ir.lifemd.com/press-release-details.php?newsId=3189112#:~:text=%D1%8D%D1%82%D0%BE%20%D1%81%D0%B0%D0%BC%D0%B0%D1%8F%20%D0%BD%D0%B8%D0%B7%D0%BA%D0%B0%D1%8F%20%D1%86%D0%B5%D0%BD%D0%B0%20%D0%BD%D0%B0%D0%BB%D0%B8%D1%87%D0%BD%D1%8B%D0%BC%D0%B8%20%D0%B2%20%D1%81%D1%82%D1%80%D0%B0%D0%BD%D0%B5%20%E2%80%94%20%D0%B7%D0%B0%20%D0%B4%D0%B2%D0%B5%20%D0%BF%D0%BE%D0%BA%D1%83%D0%BF%D0%BA%D0%B8%20%D0%B4%D0%BB%D1%8F%20%D0%BD%D0%BE%D0%B2%D1%8B%D1%85%20%D0%BF%D0%B0%D1%86%D0%B8%D0%B5%D0%BD%D1%82%D0%BE%D0%B2.">announced</a>&nbsp;earlier in the day yesterday. Under its terms, the platform will sell the pharma giant’s best-selling drugs Wegovy and Ozempic at “the lowest cash-pay pricing available nationwide.”

LifeMD stock down 25% as worsening outlook overshadows Novo Nordisk partnership news

Hims & Hers Health, Inc.

The company is vying for a market that is predicted to grow to $100 billion by the end of the decade

Pharmaceutical Companies